Differential impact of monotherapies with carbamazepine, oxcarbazepine and lamotrigine on clinically relevant laboratory values;Unterschiedlicher Effekt von Monotherapien mit Carbamazepin, Oxcarbazepin und Lamotrigin auf klinisch relevante Laborparameter

Zeitschrift fur Epileptologie

Volumn 20, Issue 3, 2007, Pages 135-142

  Staack, Anke Maren ^a   Jürges, Uta ^a   Kurth, Christoph ^a   Winkler, Christoph ^a   Steinhoff, Bernhard J ^a  

^a EPILEPSIEZENTRUM KORK   (Germany)

Author keywords

Adverse effects; Carbamazepine; Laboratory values; Lamotrigine; Monotherapy; Oxcarbazepine

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ENZYME INDUCING AGENT; LAMOTRIGINE; OXCARBAZEPINE; VALPROIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CLINICAL LABORATORY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ENZYME INDUCTION; EPILEPSY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POTASSIUM BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 34548162390     PISSN: 16176782     EISSN: 16100646     Source Type: Journal    
DOI: 10.1007/s10309-007-0260-2     Document Type: Article

References (37)

1. Krause K-H, Steinhoff BJ (1997) Nebenwirkungen von Antiepileptika. Blackwell, London Berlin
2. Schmidt D (1982) Adverse effects of antiepileptic drugs. Raven Press, New York
3. Wildemann B, Steinhoff BJ (2002) Epilepsien und Epilepsiesyndrome. In: Wildemann B, Fogel W, Grau A (eds) Therapieleitfaden Neurologie. Kohlhammer, Stuttgart, pp 377-400
4. Barragry JM, Hkin HLJ, Trafford DJH, Scott DF (1978) Effect of anticonvulsants on plasma testosterone and sex hormon binding globuline levels. Journal of Neurology Neurosurgery and Psychiatry 41:913-914
5. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllylä VV (1995) Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. European Journal of Clinocal Pharmacology 47:461-464
6. Rattya J, Turkka J, Pakarinen AJ et al (2001) Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 56:31-36
7. Kruse R (1968) Osteopathien bei antiepileptischer Langzeittherapie Monatsschrift. Kinderheilkunde 116:378-380
8. Petty, SJ, Paton, LM, O'Brien, TJ et al (2005) Effect of antiepileptic medication on bone mineral measures. Neurology 65:1358-1363
9. Traccis S, Monaco F, Sechi GP, Moglia A, Mutani R (1983) Long-term therapy with carbamazepine: Effects on nerve conduction velocity. European Neurology 22:410-416
10. Bergey K (2004) Initial treatment of epilepsy: Special issues in treating the elderly. Neurology 63 (Suppl 4):S40-S48
11. Leppik IE (2005) Choosing an antiepileptic. Selecting drugs for older patients with epilepsy. Geriatrics 60:42-47
12. Elwes RD, Binnie CD (1996) Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clinical Pharmacokinetics 30:403-415
13. Schmidt D, Sachdeo R (2000) Oxcarbazepine for treatment of partial epilepsy: A review and recommendations for clinical use. Epilepsy and Behavior 1:396-405
14. Spina E, Pisani F, Perrucca E (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clinical Pharmacokinetics 31:198-214
15. May TW, Korn-Merker E, Rambeck B (2003) Clinical Pharmacocinetiks of oxcarbazepine. Clinical Pharmacokinetics 42:1023-1042
16. Bang LM, Goa KL (2004) Spotlight on oxcarbazepine in epilepsy. CNS Drugs 18:57-61
17. Schmidt D, Elger CE (2004) How is oxcarbazepine different from carbamezepine? Der Nervenarzt 75:153-160
18. Mintzer, S, Boppana, P, Toguri, J, De-Santis, A (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47:510-515
19. Steinhoff BJ, Hirsch E, Mutani R, Nakken KO (2003) The ideal characteristics of an antiepileptic therapy: An overview of old and new AEDs. Acta Neurologica Scandinavica 107:87-95
20. Strolin Benedetti M, Ruty B, Baltes E (2005) Induction of endogenous pathways by antiepileptics and clinical implications. Fundamentals of Clinical Pharmacology 19:511-529
21. Pack AM, Morrell MJ, Marcus R et al (2005) Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Annals of Neurology 57:252-257
22. Lahr MB (1985) Hyponatremia during carbamzepine therapy. Clinical Pharmacological Therapy 37:693-696
23. Pendlebury SC, Moses DK, Eadie MJ (1989) Hyponatraemia during oxcarbazepine therapy. Human Toxicology 8:337-344
24. Van Amelsvoort T, Bakshi R, Deveaux CB, Schwabe S (1994) Hyponatremia associated with carbamazepine and oxcarbazepine therapy. A review. Epilepsia 35:181-188
25. Dong X, Leppik IE, White J, Rarick J (2005) Hyponatremia from oxcarbazepine and carbamazepine. Neurology 65:1976-1978
26. Babayigit A, Dirik E, Bober E, Cakmaci H (2006) Adverse effects of antiepileptic drugs on bone mineral density. Pediatric Neurology 35:177-181
27. Albani F, Grassi B, Ferrara R, Turrini R, Baruzzi A, PRIMO Study Group (2004) Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch. Seizure 13:254-263
28. Weintraub D, Buchsbaum R, Resor Jr SR, Hirsch LJ (2005) Effect of antiepileptic drug comedication on lamotrigine clearance. Archives of Neurology 62:1432-1436
29. May TW, Rambeck B, Jürgens U (1999) Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: Results of a retrospective study. Therapeutic Drug Monitoring 21:175-181
30. Theis JG, Sidhu J, Palmer J, Job S, Bullman J, Ascher J (2005) Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 30:2269-2274
31. Isojärvi JIT, Pakarinen AJ, Myllylä VV (1997) Basic haematological parameters, serum gamma-glutamyltransferase activity, and erythrocyte folate and serum vitamin B12 levels during carbamazepine and oxcarbazepine therapy. Seizure 6:207-211
32. Houtkooper MA, Lammertsma A, Meyer JW et al (2002) Oxcarbazepine (GP 47.680): A possible alternative to carbamazepine? Epilepsia 28:693-698
33. Lakehal F, Wurden CJ, Kalhorn TF, Levy RH (2002) Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Research 52:79-83
34. Larkin JG, Mc Klee PJW, Forrest G et al (1991) Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. British Journal of Clinical Pharmacology 31:65-71
35. Patsalos PN Elyas AA, Zakrzewska JM (1990) Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxy-carbazepine, in patients with trigeminal neuralgia. European Journal of Clinical Pharmacology 39:413-415
36. Steinhoff BJ (2004) Nebenwirkungen der Antiepileptika. In: Fröscher W, Vassella F, Hufnagel A (Hrsg) Die Epilepsien-Grundlagen, Klinik, Behandlungen, 2nd Ed. Schattauer, Stuttgart, pp 564-602
37. Steinhoff BJ, Stoll K-D, Stodieck SRG (1992) Paulus W Hyponatremic coma under oxcabazepine therapy. Epilepsy Research 11:67-70